1. Home
  2. TRVG vs IMMX Comparison

TRVG vs IMMX Comparison

Compare TRVG & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo trivago N.V.

TRVG

trivago N.V.

HOLD

Current Price

$2.77

Market Cap

211.2M

Sector

Technology

ML Signal

HOLD

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$11.19

Market Cap

306.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRVG
IMMX
Founded
2005
2014
Country
Germany
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
211.2M
306.2M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
TRVG
IMMX
Price
$2.77
$11.19
Analyst Decision
Buy
Strong Buy
Analyst Count
4
3
Target Price
$4.09
$16.33
AVG Volume (30 Days)
32.9K
570.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
14.61
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.59
N/A
Revenue Next Year
$8.42
N/A
P/E Ratio
$16.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.71
$1.34
52 Week High
$5.83
$11.45

Technical Indicators

Market Signals
Indicator
TRVG
IMMX
Relative Strength Index (RSI) 38.54 77.21
Support Level $2.77 $1.96
Resistance Level $2.93 N/A
Average True Range (ATR) 0.06 0.67
MACD -0.02 0.13
Stochastic Oscillator 16.00 88.13

Price Performance

Historical Comparison
TRVG
IMMX

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: